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Available online 9 February 2016NBS1 is an early component in DNA-Damage Response (DDR) that participates in the initiation of the responses
aiming to repair double-strand breaks caused by different mechanisms. Early steps in DDR have to react to local
alterations in chromatin that are induced by DNA damage. NBS1 participates in the early detection of DNA dam-
age and functions as a platform for the recruitment and assembly of components that are sequentially required
for the repair process. In this workwe have studiedwhether the VRK1 chromatin kinase can affect the activation
of NBS1 in response to DNA damage induced by ionizing radiation. VRK1 is forming a basal preassembled com-
plex with NBS1 in non-damaged cells. Knockdown of VRK1 resulted in the loss of NBS1 foci induced by ionizing
radiation, an effect that was also detected in cell-cycle arrested cells and in ATM (−/−) cells. The phosphoryla-
tion of NBS1 in Ser343 by VRK1 is induced by either doxorubicin or IR in ATM (−/−) cells. Phosphorylated NBS1
is also complexed with VRK1. NBS1 phosphorylation by VRK1 cooperates with ATM. This phosphorylation of
NBS1 by VRK1 contributes to the stability of NBS1 in ATM (−/−) cells, and the consequence of its loss can be
prevented by treatment with the MG132 proteasome inhibitor of RNF8. We conclude that VRK1 regulation of
NBS1 contributes to the stability of the repair complex and permits the sequential steps in DDR.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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NBN1. Introduction
Genetic damage is occurring continuously in cells as a consequence
of multiple types of genetic insults, either of endogenous or exogenous
origin [1–3]. Genetic damage is one of the main problems facing cells
during their life that has to be overcome to avoid its deleterious conse-
quences. Therefore, during evolution cells have acquired multiple
mechanisms to detect these different types of DNA damage, and to trig-
ger the immediate protective and speciﬁc DNA repair responses [3].
These mechanisms must also function in non-proliferating cells, since
most of the DNA damage occurs independently of cell division. Alter-
ations in these detection and repair mechanisms can have very serious
consequences for cells making them more sensitive to genotoxic
damage and facilitating the accumulation of mutations, but this charac-
teristic can also be exploited for therapeutic purposes [4,5]. Also the, Nijmegen breakage syndrome
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. This is an open access article underorganism can suffer important consequences, since defects in DNA re-
pair can facilitate aging [6], cancer [2] and neurodegeneration [7].
The initial alteration after DNA damage is a local distortion of the
chromatin structure, and in which histones and chromatin kinases
might be very early and initiating components in triggering the process.
Chromatin alteration can activate chromatin kinases, as is the case of
VRK1 [8–10], which can also regulate and coordinate the different
sequential steps required for successful DNA repair. VRK1 is a Ser–Thr
kinase that has been associated to the regulation of cell cycle progres-
sion [11], proliferation [8,12–14] and DNA damage responses mediated
by p53 [15,16]; and also to proteins directly involved in DDR [9]. VRK1 is
a chromatin kinase [8,10,17] that is implicated in processes requiring
chromatin remodeling, such as gene transcription and responses to
DNA damage. Thus VRK1 depletion results in defective formation of
γH2AX foci [10] and 53BP1 foci [5,9] in response to DNA damage in-
duced by ionizing radiation, even in situations of non-dividing cells [9,
10]. DNA damage responses have to be performed in each individual
cell independently of their particular situation, either cell cycle arrested
or proliferating, and of their local heterogeneous microenvironment
and cellular interactions.
NBS1/nibrin integrates the input signal from a locally altered
chromatin due to DNA damage and participates in early events of thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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breakage syndrome (NBS) is a recessive autosomal disease that includes
microcephaly, growth retardation, immune deﬁciency and increased
sensitivity to ionizing radiation among other symptoms [18]. The
Nijmegen syndrome is caused by mutations in the NBS1 gene [19],
whose protein forms part of the MRN complex (MRE11–RAD50–
NBS1) [20], and also plays a role in prevention of ataxias [21] and cere-
bellar effects [21]. Following DNAdamage, ubiquitinated NBS1 activates
ATM [22,23], a protein that is later downregulated by the ubiquitin li-
gase RNF8 [24]. NBS1 is also regulated by phosphorylation mediated
by activated ATM [25].
Homozygous mutation in the VRK1 gene causes a new neurodegen-
erative syndrome known as pontocerebellar hypoplasia with spinal
muscular atrophy (PCH1-SMA) [26]. This is a complex syndrome that
in addition to the pontocerebellar hypoplasia and muscular atrophy
there are additional symptoms such as microcephaly, mild growth re-
tardation and ataxia, but their manifestation and severity are variable
depending on the speciﬁc VRK1mutation [26–28]. More recently addi-
tional point mutations in the VRK1 gene have been identiﬁed also
presenting a complex neurological phenotype, but sharing their main
characteristics [27]. Someof these neurological symptoms are alsoman-
ifested in patients with NBS1mutations [18].
The roles of VRK1 and NBS1 in DDR independently identiﬁed share
effects suggest that there is a functional link between these twoproteins
in response to DNA damage. In this work we have studied the relation
between VRK1 and NBS1/nibrin in the context of DNA damage induced
by double strand breaks in DNA.
2. Results
2.1. VRK1 knockdown causes a loss of NBS1 foci induced by ionizing
radiation independent of ATM
NBS1 forms nuclear foci after induction of DNA damage [29],
and also the VRK1 kinase is activated by DNA damage [9,10,30]. There-
fore, we decided to study whether VRK1 knockdown might have an ef-
fect on the formation of NBS1 foci in response to ionizing radiation. This
effect was determined in several cell lines, including A549 (ATM+/+)
(Fig. 1A) and HT144 (ATM−/−) (Fig. 1B) lung carcinoma cells. Deple-
tion of VRK1 resulted in a signiﬁcant loss of NBS1 nuclear ﬂuorescence
induced by IR in both cell lines (Fig. 1). A similar result was also obtain-
ed using a different siVRK1 (Fig. S1). Since VRK1 can arrest cells in G0/
G1 [12], and in order to rule out a consequence of growth arrest, the for-
mation of NBS1was also determined in serumdeprived cells. Cells were
also able to form normal NBS1 foci induced by IR in the absence of
serum (Fig. 1A, B, bottom). Therefore, the effect of VRK1 depletion in
non-dividing cells is not a consequence of cell cycle arrest, and is also in-
dependent of ATM.
2.2. VRK1 forms a basal protein complex with NBS1
NBS1 [29] and VRK1 [10] are participants that play an early role in
reactions to DNA damage. Therefore, we hypothesized that based on
the functions of these two proteins; both are likely to form a preassem-
bled basal DDR complex in the absence of DNA damage, which is ready
to be activatedwhenDNAdamage occurs. To test this possibilitywe ﬁrst
determined whether endogenous VRK1 and NBS1 proteins could be
forming a stable protein-complex in non-damaged cells, or in cells in
which DNA damage was induced by treatment with doxorubicin. Four
cell lines were used for this aim, two ATM (+/+) (HEK293T and
A549) and two ATM (−/−) (HT144 and GM9607). The endogenous
NBS1 protein was immunoprecipitated, and the bound VRK1 protein
in the immunoprecipitate was detected by immunoblot. VRK1 was
present in the NBS1 immunoprecipitate independently of treatment
with doxorubicin, suggesting that they form a stable preassembled
complex in cells in the absence of DNA damage (Fig. 2A). This VRK1–NBS1 complex is also independent of ATM because it was also detected
in two ATM−/− cell lines. In addition, a similar protein complex was
also detected in HeLa cells in which immunoprecipitation of transfected
Flag-NBS1 brought down endogenous VRK1 independently of DNA
damage induced by doxorubicin (Fig. 2B). To further conﬁrm this
NBS1–VRK1 basal interaction, HEK293T cells were transfected with
plasmid expressing myc-VRK1 and its immunoprecipitation brought
down endogenous NBS1 independently of treatment with doxorubicin
(Fig. S2A, left). The reciprocal immunoprecipitation of transfected-
myc-VRK1 also brought down endogenous NBS1 (Fig. S2A, right). A
similar result was also obtained in cells transfected with Flag-NBS1
and HA-VRK1 (Fig. S2B). The interaction between VRK1 and NBS1 was
independent of doxorubicin treatment (Fig. S2B). Next, we determined
whether the kinase activity of VRK1was necessary to form the complex.
Cells were transfectedwith kinase-active or kinase-dead VRK1 (K179E).
The NBS1–VRK1 interaction is independent of the kinase activity of
VRK1, as shown by its interaction, with both kinase-active VRK1
(Fig. S2C) and kinase-dead VRK1 (KD: K179E) in pulldown experiments
(Fig. S2D). All these results conﬁrmed the formation of a stable and basal
NBS1–VRK1 protein complex in the absence of DNA damage.
2.3. VRK1 phosphorylates NBS1 in Ser343
The possible effect of VRK1 on NBS1 is likely to be a consequence of
its kinase activity as a result of VRK1 activation by DNA damage [9].
Thus, in order to identify the NBS1 amino acid residue phosphorylated
in vitro by VRK1, the phosphorylation of NBS1 was studied with a
phosphospeciﬁc antibody recognizing that NBS1 is phosphorylated in
Ser343,with andwithout treatmentwith doxorubicin or ionizing irradi-
ation. NBS1-Ser343 was phosphorylated in response to treatment with
doxorubicin and ionizing radiation in both A549 (Fig. 3A) and HT144
(ATM−/−) cells (Fig. 3B). Depletion of VRK1 with siRNA resulted in
the loss of NBS1 phosphorylation in Ser343 induced by doxorubicin or
IR in both cell lines (Fig. 3A, B). In cells that were neither irradiated
nor treated with doxorubicin there was no phosphorylation of NBS1 in
Ser343 (Fig 3A, B, left panel).
Next we determined if both NBS1 and its Ser-343 phosphorylated
form could be detected forming a stable protein complex with VRK1.
For this aim, endogenous NBS1 protein from non-irradiated and irradi-
ated cell extracts were immunoprecipitated and the presence of VRK1
and NBS1 phosphorylated in Ser343 determined in the immunoprecip-
itate. Phosphorylation of NBS1 in Ser343was only detected in irradiated
cells, but the presence of VRK1 was detected in the NBS1 immunopre-
cipitate independent of its treatment (Fig. 3C).
To conﬁrm the phosphorylation of NBS1, cells were transfected with
empty vector (AU5) or a plasmid expressing AU5-NBS1. The transfected
protein was immunoprecipitated and incubated with bacterially
expressed GST-VRK1. The GST-VRK1 protein phosphorylated NBS1,
which was detected with an anti Ser343-P phosphospeciﬁc antibody
(Fig. 3D). Nextwe determined if the loss of VRK1 kinase activity affected
this phosphorylation of NBS1. For this aim, kinase-dead GST-VRK1
(K179E) was used. Kinase active, but not kinase-dead VRK1 phosphory-
lated NBS1 (Fig. 3E).
2.4. VRK1 depletion reduces the level of NBS1 protein in ATM−/− cells that
is prevented by proteasome inhibitors
The depletion of VRK1 could affect the formation of NBS1 foci by two
alternative mechanisms, either altering gene expression or protein sta-
bility. Theﬁrstmechanismwill result in a reduction of theNBS1 gene ex-
pression and consequently of its protein level.
The effect that VRK1 depletion has on the level of NBS1 protein and
RNA after DNA damage induced by ionizing radiation or doxorubicin
was determined in HT144 (ATM−/−) (Fig. 4A) and A549 (ATM+/+)
cells (Fig. 4B). Loss of VRK1 did not affect NBS1 protein levels in A549
cells (Fig. 4B), thus VRK1 effect on NBS1 foci is not due to NBS1 stability.
Fig. 1. Effect of VRK1 knockdown on the formation of NBS1 foci induced by ionizing radiation. A. A549 (ATM+/+) cells were either transfected with siControl (si-Ct) or siVRK1 (si-V02)
and irradiated. NBS1 and VRK1 were detected with speciﬁc antibodies. The immunoblot to the right show the protein levels and the graph the quantiﬁcation of the ﬂuorescence. The
number of cells counted is indicated below. B. HT144 (ATM−/−) cells were either transfected with si-Control (si-Ct) or siVRK1-02 (si-V02) and irradiated. NBS1 and VRK1 were
detected with speciﬁc antibodies. The immunoblot to the right show the protein levels and the graph the quantiﬁcation of the ﬂuorescence. The number of cells counted is indicated
below. ***P b 0.001.
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in the absence of ATM resulted in loss of NBS1 protein (Fig. 4A). These
data suggested that ATM and VRK1 are necessary for the stability of
NBS1, in addition to their role in the formation of NBS1 foci, although
this protection can only be achieved by the additional presence ofVRK1.We also ruled out that VRK1 depletion did not alterNBS1 gene ex-
pression. The levels of NBS1 gene expressionwere not affected by VRK1
depletion using different siRNA and were determined by qRT-PCR in
RNA from A549 and HT144 cells (Fig. 4C).Therefore, VRK1 knock-
down reduced the level of VRK1, but not of NBS1.
Fig. 2. NBS1 interactswith VRK1 independently of ATMandofDNAdamage. A.Detection of the interaction between endogenousproteins inHEK-293T, A549, both ATM (+/+)andHT144
and GM9607 cell lines that are ATM(−/−). Cells were untreated or treatedwith 1 μM doxorubicina (Doxo) for 2 h. Cell lysates were used for immunoprecipitation with antibody control
(anti-AU5) or anti-NBS1. Immunoprecipitates were used for detection of VRK1withmAb 1B5 and anti-NBS1. B. Reciprocal immunoprecipitation of NBS1 and VRK1. For this experiment a
stable HeLa pooled cells overexpressing VRK1 by infection with pQCXIP-VRK1. Reciprocal immunoprecipitation was performed and antiAU5 antibody was used as negative control. The
interaction was conﬁrmed in transiently transfected cells with VRK1 and NBS1 plasmids (Fig. S1).
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mation of NBS1 foci is by altering the stability of the NBS1 protein. The
effect of VRK1 knockdown on NBS1 stability could be a consequence
of altering its sensitivity to active protein degradation mediated by
the proteasome. The use of the proteasome inhibitor MG132 was able
to prevent the downregulation of NBS1 as a consequence of VRK1
knockdown only in HT144 cells lacking ATM (Fig. 4D). This means
that VRK1 phosphorylation cooperates with the additional phosphory-
lation of NBS1 mediated by ATM. However, this effect was not affected
by lysosomal inhibitors such as chloroquine (not shown). Next, it was
determined the protective effect of the proteasomal inhibitor MG132
on NBS1 foci in two ATM−/− cell lines, HT144 (Fig. 5A) and GM9607
(Fig. 5B). The addition of the proteasomal inhibitor MG132 resulted in
the recovery of the NBS nuclear ﬂuorescence induced by ionizing radia-
tion in both ATM (−/−) cell lines in which VRK1 was knocked-down
(Fig. 5). These observations indicated that phosphorylation of NBS1 in
Ser343protects it from its proteasomal degradation. By thismechanism,
the temporal organization of DNA repair foci can be remodeled to facil-
itate their sequential, but functionally different, steps.2.5. RNF8 is part of the NBS1–VRK1 complex
NBS1 is a known target of the RNF8 ubiquitin ligase [24]. Therefore,
we tested whether NBS1–RNF8 complexes were also containing VRK1.
For this aim we tested the formation of a protein complex by transfec-
tion of different combinations of tagged-plasmids expressing NBS1,
RNF8 and VRK1 proteins. The immunoprecipitation of RNF8 by itself
was able to bring down NBS1, and also VRK1 when it was included
(Fig. 6A). Next, we determinedwhether theVRK1–NBS1–RNF8 complex
was altered in cells treated with doxorubicin. The RNF8 immunoprecip-
itate always contained VRK1, independent of DNA damage treatment
(Fig 6B). This observation is consistent with the existence of a preas-
sembled NBS1–VRK1 complex.
Because RNF8 is an ubiquitin ligase we determined if it affected
VRK1 and NBS1 levels. In HT144 (ATM−/−) cells both proteins were
sensitive to degradation induced by RNF8 in a dose dependent manner
(Fig. 6C, left). However, in A549 (ATM+/+) cells, both proteins were
resistant to RNF8 and their levels remained stable (Fig. 6C, right), indi-
cating that an additional contribution by ATM was necessary to main-
tain the stability of NBS1 protein.3. Discussion
The immediate response to DNA damage requires that its initial par-
ticipants form a preassembled complex on chromatin, which can be im-
mediately reorganized and relocated to the site of DNA damage. This
relocation can initiate and trigger the recruitment of the proteins partic-
ipating in the sequential steps of the speciﬁc DNA repair process. The
formation of a preassembled protein complex between p53 and VRK1
has already been detected and is critical for the cellular responses
to DNA damage response mediated by p53 activation [31,32]. The
preassembled complex leads to the immediate activation of p53 by
phosphorylation in Thr18 [30] resulting in a switch to binding transcrip-
tional cofactors [33]. Therefore, among early participants in DDR,
chromatin kinases and scaffold proteins are likely candidates for this
function since they can integrate the assembly of consecutive signaling
complexes. Among these, the formation of a basal protein complex be-
tween NBS1 and VRK1 is a very likely component for this early role in
DDR. VRK1 as chromatin kinase can participate in the processes requir-
ing dynamic modiﬁcations of chromatin that are associated to speciﬁc
chromatin functions, such as DDR, chromatin condensation and telo-
mere assembly and protection. The direct interaction of VRK1 with his-
tones [8,10] and its regulation [17] can function as the initial step that
permits reacting to local alterations of chromatin in response to DNA
damage, and as part of the signal that activates early components in
DDR, amongwhich NBS1 is a key player [34]. Therefore, VRK1 can be in-
tegrated in the cellular interactome reacting to DNA damage at different
functional levels (Fig. 7), such as chromatin components at the local site
of DNA damage, as well as the response to cellular damagemediated by
p53, which is a target of VRK1 [16,35–37] and that also forms a preas-
sembled complex with VRK1 [30].
The role of VRK1 on NBS1 foci induced by ionizing radiation can
have different roles. One is that NBS1 foci formation is prevented be-
cause VRK1 is acting as an upstream component by participating in
the formation of γH2AX foci induced by IR [10], which is a trigger to ini-
tiate speciﬁc DDR responses. NBS1 interacts by its FHA/BRCT domain
with γH2AX [38]. The permanence of VRK1 in the complex with the
NBS1 phosphorylated molecule suggested that VRK1 is also likely to
participate at later, or downstream, steps in DDR. This is consistent
with the observation that VRK1 is also able to regulate the formation
of 53BP1 foci, an intermediate participant in DNA repair by NHEJ [9].
The other is acting downstream and thus permitting the sequential
Fig. 3. Effect of VRK1 depletion on the induction of NBS1 phosphorylation in Ser343 induced by DNA damage. A. A549 (ATM+/+) cells were used for depletion of VRK1 and treatedwith
doxorubicin or ionizing radiation. The levels of VRK1, NBS1 andNBS1-Ser343-Pwere determinedwith speciﬁc antibodies in cell lysates. B. HT144 (ATM−/−) cellswere used for depletion
of VRK1 and treated with doxorubicin or ionizing radiation. The levels of VRK1, NBS1 and NBS1-Ser343-P were determined with speciﬁc antibodies in cell lysates. C. Both NBS1 non-
phosphorylated and NBS1 phosphorylated in Ser343 form a complex with VRK1. Cells were used as controls or treated with ionizing radiation. Cell lysates were used for
immunoprecipitation of NBS1. In input lysate and in the immunoprecipitate the presence of VRK1, NBS1 and NBS1-Ser343P was determined. D. Phosphorylation of NBS1 by VRK1 in
in vitro kinase assay. Bacterially expressed and puriﬁed GST-VRK1 was used in kinase assays with immunoprecipitated endogenous NBS1 protein. In the assay the speciﬁc VRK1, NBS1
and NBS1-Ser343P were detected with speciﬁc antibodies. E. In vitro kinase assay with VRK1 active and kinase-dead (KD: kinase dead, substitution K179E) proteins. Endogenous NBS1
was immunoprecipitated and used as substrate. VRK1, NBS1 and NBS1-Ser343P were detected with speciﬁc antibodies.si-Ct: control; siV-02: si-VRK1-02. pNBS: NBS1 phosphorylated
in Ser343.
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the removal of NBS1 is necessary to allow other proteins to function in a
correct and organized sequential order. In this context, the role of VRK1
on NBS1 Ser343 phosphorylation is a contributor to a downstream
regulation.
NBS1 phosphorylation in Ser343 has been associated to S phase pro-
gression [39,40], although it has been proposed to be mediated by ATM
this kinase downstream of NBS1 [22] and 53BP1 [41]. Nevertheless,
the phosphorylation of this Ser343 by VRK1 in cells lacking ATM sug-
gests that VRK1 is the initial upstream kinase implicated since it phos-
phorylates NBS1 in the absence of ATM, and is activated in cell cycle
progression, a role also associated to VRK1 [9,10]. This implies that the
two kinases play a cooperative role in DNA damage response. In addi-
tion to ATM, NBS1 is also phosphorylated in Ser432 by CDK in cell
cycle progression [42]. This phosphorylation participates in the reces-
sion of the DNA lesion, a later stage in the process of DNA repair [42].
VRK1 depletion also prevents the activating phosphorylation of ATM
in Ser1981 [9,10]. This ATM phosphorylation is mediated by autophos-
phorylation of ATM and is thus a likely consequence of the responseto a chromatin that is locally altered by DNAdamage,which is an activa-
tor of VRK1 [10,30].
NBS1 is ubiquitinated by several ubiquitin ligases in different residues
that canplay different functional roles. NBS1ubiquitination in Lys735 and
Lys751 by Skp2 facilitates ATM activation in homologous recombination
[43]. NBS1 ubiquitination in Lys435 is a key residue targeted by RNF8,
which forms a complex with NBS1 [24]. The ubiquitination of NBS1 by
RNF8 has been associated to DNA repair by homologous recombination
[24], however the role of NBS1 ubiquitination in non-dividing cells
that repair DNA double-strand breaks by NHEJ is not known. In this
work we show that the phosphorylation of NBS1 by VRK1 is necessary
to protect NBS1 from degradation that will facilitate progression
to the assembly of complexes with speciﬁc repair functions, such
as 53BP1 that is a selector of the NHEJ pathway [9,41]. Thus, in the ab-
sence of DNA damage and cell division there is a preassembled repair
complex that includes VRK1–NBS1 and RNF8 that might be a key com-
ponent for the activation and early steps in DDR. Formation of a basal
complex that contains NBS1, RNF8 and VRK1, suggested that it is likely
to be a complex playing an immediate response system in case DNA
Fig. 4.VRK1depletion alters the levels of NBS1 protein only in ATM (−/−) cells. A. Effect of VRK1 knockdown in A549 (ATM+/+) cells on the level of NBS1 protein after induction of DNA
damage by doxorubicin or ionizing radiation. NBS1 and VRK1were detected by immunoblots of cell lysates. B. Effect of VRK1 knockdown in HT144 (ATM−/−) cells on the level of NBS1
protein after induction of DNA damage by doxorubicin or ionizing radiation. NBS1 and VRK1 were detected by immunoblots of cell lysates. C. Effect of VRK1 knockdown in HT144
(ATM−/−) cells on the level of NBS1 RNA determined by qRT-PCR. D. Effect of the MG123 proteasome inhibitor on the reduction of NBS1 levels induced by VRK1 knockdown in
HT144 (ATM−/−) cells.
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43] contribute to increased resistance to DNA damage induced by
drugs or IR.
The role of VRK1 in the regulation of NBS1 in the context of DNA
damage response indicates that the targeting of VRK1 can be of poten-
tial use for therapeutic purposes. The loss of VRK1, in addition to its in-
terference with cell proliferation [11,12], also results in defective
formation of γH2AX [10] and 53BP1 [5,9] foci in response to DNA dam-
age and in that way sensitizes cells to gamma irradiation or chemother-
apy. The atypical structure of VRK1 makes feasible the design of highlyspeciﬁc inhibitors with little or no cross reactivity with other kinases
[44–46]. Future development of speciﬁc VRK1 inhibitors would greatly
facilitate a reduction in tumor proliferation and facilitate cell death by
sensitizing cells to DNA damage, which implies a likely reduction of
the dose for radiotherapy or chemotherapy [5]. This is important be-
cause kinase inhibitors are better tolerated than chemotherapeutic
drug based DNAdamage. Thus the combination of these drugswith spe-
ciﬁc kinase inhibitors could reduce the toxicity of the treatment. How-
ever, the structural characteristics of the VRK1 protein [44] make most
currently available inhibitors unsuitable [46], since they only have a
Fig. 5. Loss of NBS1 foci induced by IR after VRK1 knockdown is prevented by proteasomal inhibition in ATM−/− cells. A. HT144 (ATM−/−) cells were transfected with si-Control (siCt)
or siVRK1-02 (siV-02) and 96 h later cells were irradiated with 3 Gy. The proteasomal inhibitor MG132 (50 μM)was added to cultures 6 h before irradiation. At the bottom is shown the
quantiﬁcation of NBS1 ﬂuorescence. ***P b 0.001. B. GM9607 (ATM−/−) cells were transfectedwith si-Control (siCt) or siVRK1-02 (siV-02) and 96 h later cells were irradiatedwith 3 Gy.
The proteasomal inhibitor MG132 (50 μM)was added to cultures 6 h before irradiation. At the bottom is shown the quantiﬁcation of NBS1 ﬂuorescence. ***P b 0.001. NBS1 was detected
with a monoclonal antibody and VRK1 with a policlonal antibody. Nuclei were identiﬁed by staining with DAPI.
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targeting VRK1 have been identiﬁed, such a luteolin [47] or ursolic acid
[48], but in both cases the speciﬁcity is unknown, and doses in millimo-
lar range are required to have an effect.
In this report we have identiﬁed a preassembled NBS1–VRK1 com-
plex that is activated by DNA damage and that contributes to the stabil-
ity of NBS1 thus facilitating the sequential steps in DDR.
4. Materials and methods
4.1. Plasmids
NBS1 constructs pCDNA3-myc-NBS1 [24]; pIRES2-NBS1-GST and
pIRES2-NBS1-FLAG were obtained from J. Chen [49].VRK1 constructs
pGEX4-GST-VRK1 [35], pCEFL-GST-VRK1 [50,51], and pCEFL-HA-VRK1
[37,50] have already been reported. Empty plasmid vectorswith speciﬁc
epitope tags, such as AU5, Flag, myc or GST, were used in theappropriate transfection experiment as controls of plasmids expressing
tagged proteins.
4.2. Cell lines, culture and transfections
A549, H1299 (p53−/−), HT144 (ATM−/−), GM9607 (ATM−/−),
HeLa and HEK293T cell lines were from the ATCC. Cells were grown as
recommended by the supplier in DMEM supplementedwith antibiotics,
10% FBS and 5 mM glutamine. Plasmid transfections were performed
using the Jet-Pei reagent (Polytransfection Plus, Illkirch, France) accord-
ing to the manufacturer's instructions [52].
4.3. RNA interference
Speciﬁc silencing of VRK1was performed using two different siRNA:
siVRK1-01 (siV1-01) and siVRK1-02 (siV1-02) from Dharmacon
(Dharmacon RNA Technologies). The sequence target of the two VRK1
Fig. 6. NBS1, RNF8 and VRK1 interactions. A. HEK-293T cells were transfected with
plasmids pCMV-FLAG-NBS1, pcDNA3.1-HA-RNF8 and pCDNA3.1-VRK1-Myc as indicated.
HA-RNF8 was immunoprecipitated with an anti-HA policlonal antibody and NBS1 and
VRK1 were detected in an immunoblot blot with antibodies speciﬁc for their tags.
B. HEK-293T cells were transfected with plasmids pcDNA3.1-HA-RNF8 and pCEFL-GST-
VRK1. HA-RNF8 was immunoprecipitated with an anti-HA policlonal antibody; the
presence of VRK1 in the immunoprecipitate was determined with an anti-GST antibody.
C. Dose dependent effect of RNF8 on endogenous NBS1 and VRK1. Plasmid pcDNA3.1-
HA-RNF8 was transfected in HT144 (left) and A549 (right) cells. Protein levels were
determined in immunoblots with polyclonal antibodies speciﬁc for NBS1 or VRK1. The
total amount of plasmid in each transfection was always constant by completing it with
the corresponding empty vector.
767D.M. Monsalve et al. / Biochimica et Biophysica Acta 1863 (2016) 760–769siRNA oligos was siVRK1-01: GAAAGAGAGTCCAGAAGTA and siVRK1-
02: CAAGGAACCTGGTGTTGAA. As negative control, indicated as siCt in
experiments, the “ON-TARGETplus siCONTROL Non-targeting siRNA”
from DHARMACON was used. The efﬁciency of RNAi transfection was
determined with “siGLO RISC-free siRNA” (Dharmacon).
Brieﬂy, cells were transfected with the indicated siRNA at a con-
centration of 20 nM using Lipofectamine 2000 Reagent (Invitrogen) ac-
cording to themanufacturer's instructions. After transfection, cells were
processed at the times indicated in speciﬁc experiment that were per-
formed as previously reported [9,15]. Targeted protein and plasmid ex-
pression was analyzed 36 h after transfection.
4.4. Antibodies
VRK1 was detected with monoclonal antibody 1F6 [53], polyclonal
antibody VC1 [53] or polyclonal antibody (HPA017929, Sigma). NBS1
(residues 692–706) with murine monoclonal (611871, BD Bioscience,
San José, CA), or polyclonal antibody (N3162, Sigma, St. Louis, MO).
NBS1-Ser-343-P with rabbit polyclonal antibody (3001, Cell Signaling).
NBS1-Ser432-Pwith rabbit monoclonal antibody (LS-c105367, LifeSpan
Biosciences, Seattle, WA). Myc epitope with murine monoclonal orrabbit polyclonal antibodies (EMD-Millipore, Darmstadt, Germany).
The ﬂag epitope was detected with a polyclonal antibody (F7425,
Sigma) ormonoclonal antibodies (clonesM2orM5, Sigma). TheHAepi-
tope was detected with a murine monoclonal (sc-7392, Santa Cruz,
Santa Cruz, CA) or rabbit polyclonal antibody (H6908, Sigma). GST
with detected with a rabbit polyclonal antibody (sc-138, Santa Cruz).
4.5. Immunoprecipitations
Immunoprecipitations were prepared using 1.5 mg of whole cell
extracts. Cells were lysed and to avoid nonspeciﬁc interactions, cell
extracts were preincubated with 30 μL of “GammaBind Plus Sepharose”
beads (GE Healthcare) equilibrated in the same buffer as the extracts,
and incubated for 1 h at 4 °C with orbital rotation. The beads were
removed by centrifugation and extracts were incubatedwith the specif-
ic antibody indicated in the experiment for 3 h. Afterwards, 40 μL of
“GammaBind Plus Sepharose” beads, which have been previously
blocked with seroalbumin (BSA), was added and incubated for 2–3 h
or overnight at 4 °C with rotation. Next, the resin was washed several
times in lysis buffer, before processing for gel loading. The immunopre-
cipitatewas fractionated by SDS-PAGE, and the gel transferred to a PDVF
membrane, Immobilon-P (Millipore), for immunoblot analysis. All
methods have been previously reported [15,52–55]. The VRK1–NBS1
protein interaction has been assigned the identiﬁer IM-24744 by the
IMEX consortium [56].
4.6. DNA damage
DNA damage was induced by cell irradiation with 3 Gy using a
Gammacell 1000 Elite irradiator (Theratronics, Ottawa, Canada) with a
137Cs source. Cells were treated with doxorubicin (Sigma, St. Louis,
MO) for the time and dose indicated in individual experiments [5,9,10].
4.7. Immunoﬂuorescence and confocal microscopy
Cells were grown on cover slides treated with 0.01% poly-lysine, to
improve their adherence, washed in cold PBS and ﬁxedwith 3% parafor-
maldehyde in PBS for 30 min at room temperature. After ﬁxation, they
were washed with 0.2 M glycine followed by permeabilization with
0.2% Triton X-100 in PBS for 30 min and blocking with 1% BSA in PBS
for 30 min at room temperature. Following antibody incubations cells
were washed three times with PBS for 5 min. Secondary antibodies la-
beled with Cy2 or Cy3 were diluted in blocking buffer and incubation
was performed for 1 h at room temperature. Nuclei were stained with
DAPI (4′,6′-diamidine-2-fenilindol), diluted in PBS and incubated for
10 min at room temperature. Cells were washed three times for 5 min
in PBS and a ﬁnal wash in distilled water. Coverslips were mounted on
a slide with MOWIOL 4-88 (Calbiochem). Subcellular localization was
determined by confocalmicroscopy. The acquisition of images by confo-
cal microscopy has already been reported [5,9,10] using a Leica TCS SP5
DMI-6000B confocal microscope (Leica), using the following lasers:
Argon (488 nm), DPSS (561 nm) and UV diode (405 nm). Fluorescent
images were captured with a 63.0× lens zoomed in 1.5–3× with a
1024 × 1024 frame and 600 Hz scanning speed. Images were analyzed
with Leica LAS AF (Leica) and ImageJ (NIH, http://rsb.info.nih.gov/ij)
software.
4.8. Kinase assays
The radioactive kinase assay was performed using bacterially
expressed and puriﬁed GST-VRK1 and using as substrate immuno-
precipitated NBS1. Speciﬁc phosphorylationwas detectedwith amono-
clonal antibody. The kinase assay conditions have been previously
reported [46,57].
Fig. 7. The interactome of VRK1. The protein interaction network of VRK1 has been generated with the Cytoscape program (www.nih.gov) using validated protein–protein interactions
from the IntAct Molecular Interaction Database (www.ebi.ac.uk/intact).
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Quantitative experiments were performed at least three times, the
number of cells is indicated and statistical analysis was performed by
the ANOVA two-way test using the IBM SPSS 21 statistics package.
4.10. Database of protein interactions
The protein interactions from this publication have been submitted
to the IMEx.
(http://www.imexconsortium.org) consortium through IntAct data-
base and assigned the identiﬁer IM-24744 [56].
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2016.02.005.
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